Natural Product (NP) Details
General Information of the NP (ID: NP1214) | |||||
---|---|---|---|---|---|
Name |
Wedelolactone
|
||||
Synonyms |
7-Methoxy-5,11,12-trihydroxycoumestan; 7-Methoxy-5,11,12-trihydroxy-coumestan; 1,8,9-Trihydroxy-3-methoxycoumestan; Wedelolactone, Eclipta alba; CHEMBL97453; 0K6L725GNS; CHEBI:10037; IKK Inhibitor II, Wedelolactone; 1,8,9-Trihydroxy-3-methoxy-6H-benzofuro[3,2-c][1]benzopyran-6-one; 1,8,9-trihydroxy-3-methoxy-benzofuro[3,2-c]chromen-6-one; 1,8,9-Trihydroxy-3-methoxy-6H-[1]benzofuro[3,2-c]chromen-6-one; AC1NQZ4Z; SCHEMBL601220; GTPL5551; CTK8G3781; DTXSID60200408; Wedelolactone, analyti; 524-12-9; UNII-0K6L725GNS
Click to Show/Hide
|
||||
Species Origin | Eclipta prostrata ... | Click to Show/Hide | |||
Eclipta prostrata | |||||
Disease | Keratitis [ICD-11: 9A71] | Investigative | [1] | ||
Structure |
![]() |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C16H10O7
|
||||
PubChem CID | |||||
Canonical SMILES |
COC1=CC(=C2C(=C1)OC(=O)C3=C2OC4=CC(=C(C=C43)O)O)O
|
||||
InChI |
1S/C16H10O7/c1-21-6-2-10(19)14-12(3-6)23-16(20)13-7-4-8(17)9(18)5-11(7)22-15(13)14/h2-5,17-19H,1H3
|
||||
InChIKey |
XQDCKJKKMFWXGB-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 524-12-9
|
||||
Herb ID | |||||
ETMC ID | |||||
SymMap ID | |||||
TCMSP ID | |||||
TTD Drug ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
Cisplatin | Bladder cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
In-vitro Model | HeLa | CVCL_0030 | Endocervical adenocarcinoma | Homo sapiens | ||
Experimental
Result(s) |
Sequential combination of cisplatin with wedelolactone showed synergistic antitumor effect in cervical cancer cells. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Gamma-aminobutyric acid receptor (GAR) | Molecule Info | [3] |
